About this item:

752 Views | 725 Downloads

Author Notes:

Address correspondence to Heidi M. Soeters, hsoeters@email.unc.edu Present address: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

We thank the Group for Enteric, Respiratory, and Meningeal Disease Surveillance in South Africa (GERMS-SA), the Respiratory and Meningeal Pathogens Research Unit (RMPRU) team, and all participating hospitals and laboratories for their surveillance efforts.

GERMS-SA, 2003–2007: Sandeep Vasaikar (Eastern Cape); Nolan Janse van Rensberg, André Möller, Peter Smith, Anne-Marie Pretorius (Free State); Khatija Ahmed, Anwar Hoosen, Ruth Lekalakala, Pyu Pyu Sein, Charles Feldman, Alan Karstaedt, Olga Perovic, Jeannette Wadula, Mike Dove, Kathy Lindeque, Linda Meyer, Gerhard Weldhagen (Gauteng); Stan Harvey, Pieter Jooste (Northern Cape); Danie Cilliers (North West Province); Wim Sturm, Trusha Vanmali, Prathna Bhola, Prashini Moodley, Sindiswe Sithole, Halima Dawood (KwaZulu Natal); Ken Hamese (Limpopo); Keith Bauer, Greta Hoyland, Jacob Lebudi, Charles Mutanda (Mpumalanga); Rena Hoffmann, Siseko Martin, Lynne Liebowitz, Elizabeth Wasserman, Andrew Whitelaw (Western Cape); Adrian Brink, Inge Zietsman, Maria Botha, Xoliswa Poswa, Mark da Silva, Suzy Budavari (Ampath laboratories); Claire Heney, Juanita Smit (Lancet laboratories); Marthinus Senekal (Pathcare laboratories); Cheryl Cohen, Mireille Cheyip, Leigh Dini, Linda de Gouveia, John Frean, Nelesh Govender, Susan Gould, Karen Keddy, Kerrigan McCarthy, Susan Meiring, Elizabeth Prentice, Vanessa Quan, Jeffrey Ramalivhana, Arvinda Sooka, and Anne von Gottberg (National Institute for Communicable Diseases).

We report no conflicts of interest.

Subjects:

Research Funding:

This work was supported by the Rollins School of Public Health Global Field Experience Global Frameworks Grant (to H.M.S.); the Rollins School of Public Health Student Initiative Fund (to H.M.S.); the United States Agency for International Development's Antimicrobial Resistance Initiative, transferred via a cooperative agreement (number U60/CCU022088) from the Centers for Disease Control and Prevention (CDC), Atlanta, GA (2003 to 2006); and the CDC, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Global AIDS Program (GAP) cooperative agreement U62/PSO022901(2005 to 2007).

The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of CDC.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Microbiology
  • Pharmacology & Pharmacy
  • MICROBIOLOGY
  • PHARMACOLOGY & PHARMACY
  • STREPTOCOCCUS-PNEUMONIAE
  • SOUTH-AFRICA
  • ANTIRETROVIRAL THERAPY
  • CHILDREN
  • HIV
  • COTRIMOXAZOLE
  • IMPACT
  • RESISTANCE
  • CARRIAGE
  • TRIAL

Trimethoprim-Sulfamethoxazole Prophylaxis and Antibiotic Nonsusceptibility in Invasive Pneumococcal Disease

Tools:

Journal Title:

Antimicrobial Agents and Chemotherapy

Volume:

Volume 56, Number 3

Publisher:

, Pages 1602-1605

Type of Work:

Article | Final Publisher PDF

Abstract:

Among 5,043 invasive pneumococcal disease (IPD) isolates identified through South African national surveillance from 2003 to 2007, we estimated the effect of trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis on antimicrobial resistance. Patients on TMP-SMX prophylaxis were more likely to have a pneumococcal isolate nonsusceptible to TMP-SMX, penicillin, and rifampin. TMP-SMX nonsusceptibility was associated with nonsusceptibility to penicillin, erythromycin, and rifampin and multidrug resistance. This study informs empirical treatment of suspected IPD in patients with a history of TMP-SMX use.

Copyright information:

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Export to EndNote